Search Results 71-80 of 19086 for ulcerative colitis

  1. Scott Hennen on Ulcerative Colitis and Mayo Clinic

    ... ulcerative colitis, which was first diagnosed in 1997. Scott had previously described his reasons for being public about his medical condition in this post ...

  2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Ulcerative Colitis - Mayo Clinic

    ... Ulcerative Colitis. Print details. Share; Facebook · Twitter. Overview; Participation eligibility; Participating Mayo Clinic info; More information. Overview.

  3. Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC) - Mayo Clinic

    Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC) · Overview · Participation eligibility · Participating Mayo Clinic locations · More information ...

  4. Inflammatory Bowel Disease (IBD) Clinical Trials - Mayo Clinic Research

    ... ulcerative colitis or Crohn's disease. This new vaccine has been found to be more effective than the existing vaccine Engerix in people without ulcerative ...

  5. Head-to-head comparison between vedolizumab and adalimumab for treatment of moderately to severely active ulcerative colitis - Mayo Clinic

    The Food and Drug Administration approved the use of anti-tumor necrosis factor and anti-integrin agents for the treatment of ulcerative colitis in 2005 ...

  6. Ulcerative colitis — a disease that causes ulcers and swelling called inflammation in the lining of the large intestine. Causes shown here are commonly ...

  7. Balsalazide (oral route) - Side effects & dosage - Mayo Clinic

    Balsalazide capsules are used to treat mild to moderately active ulcerative colitis in patients 5 years of age and older. Balsalazide tablets are used to ...

  8. Vedolizumab IV in Pediatric Participants With Ulcerative Colitis or Crohn's Disease - Mayo Clinic

    ... ulcerative colitis or Crohn's disease. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous ...

  9. Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies - Mayo Clinic

    ... ulcerative colitis (UC) participants previously enrolled in etrolizumab Phase II/III studies. Participants with moderate to severe UC who were enrolled in ...

  10. Mesalamine (rectal route) - Side effects & dosage - Mayo Clinic

    Mesalamineenema is used to treat active mild to moderate ulcerative colitis, proctitis or proctosigmoiditis (inflammation of the rectum and bowel). It works ...